Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0EZNOG
ADC Name	Anti-HER2_vc-1
Synonyms	Anti-HER2-vc-1; anti-HER2 vc-1 Click to Show/Hide
Drug Status	Investigative
Indication	In total 1 Indication(s) Breast cancer [ICD11:2C60-2C65] Investigative
Drug-to-Antibody Ratio	8.7
Structure
	3D MOL	2D MOL
Antibody Name	Trastuzumab		Antibody Info
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)		Antigen Info
Payload Name	TLR7 agonist-1		Payload Info
Therapeutic Target	Toll-like receptor 7 (TLR7)		Target Info
Linker Name	Mc-Val-Cit-PABC		Linker Info
Conjugate Type	The free sulfhydryl group obtained by the reduction of interchain cysteine is site-specific conjugated with maleimide, michael addition reaction.

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 96.2	%	HCC1954 cells	Breast ductal carcinoma
Tumor Growth Inhibition value (TGI)	≈ 100	%	HCC1954 cells	Breast ductal carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.20% (Day 30)	High HER2 expression (HER2+++)
Method Description	Approximately 2 million cells (100 L of the mixture) were implanted subcutaneously to the right flank of 68 weeks old female SCID/beige mice. After the tumors reached about 200 to 400 mm³ ,the mice were treated with either anti-HER2_vc-1 or non-targeted ADC at 3 mpk (IP,Q5dx3).
In Vivo Model	Breast cancer CDX model
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 30)	High HER2 expression (HER2+++)
Method Description	Approximately 2 million cells (100 L of the mixture) were implanted subcutaneously to the right flank of 68 weeks old female SCID/beige mice. After the tumors reached about 200 to 400 mm³ ,the mice were treated with either anti-HER2_vc-1 or non-targeted ADC at 10 mpk (IP,Q5dx3).
In Vivo Model	Breast cancer CDX model
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259

References

Ref 1	Design and Characterization of Immune-Stimulating Imidazo[4,5-c]quinoline Antibody-Drug Conjugates. Mol Pharm. 2022 Sep 5;19(9):3228-3241.